Meritain Eldorado policies

Search Meritain Eldorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

67 policies name J1100, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Eldorado policies
PolicyDetailsCodesSource
0899-Elotuzumab (Empliciti)0899 · Commercial11Original policy ↗
0981-Belantamab Mafodotin-blmf (Blenrep)0981 · Commercial13Original policy ↗
0969-Isatuximab-irfc (Sarclisa)0969 · Commercial14Original policy ↗
0948-Emapalumab-lzsg (Gamifant)0948 · Commercial18Original policy ↗
1077-Remestemcel-L-rknd (Ryoncil)1077 · Commercial19Original policy ↗
0919-Inotuzumab Ozogamicin (Besponsa)0919 · Commercial22Original policy ↗
Hammertoe Repair0636 · Commercial26Original policy ↗
0884-Siltuximab (Sylvant)0884 · Commercial28Original policy ↗
0946-Ravulizumab-cwvz (Ultomiris)0946 · Commercial28Original policy ↗
1035-Rozanolixizumab-noli (Rystiggo)1035 · Commercial28Original policy ↗
1075-Zanidatamab-hrii (Ziihera)1075 · Commercial30Original policy ↗
Hip Arthroplasty0287 · Commercial33Original policy ↗
0875-Bendamustine Products0875 · Commercial34Original policy ↗
Bunionectomy0629 · Commercial35Original policy ↗
Rilonacept (Arcalyst)0770 · Commercial35Original policy ↗
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes0627 · Commercial36Original policy ↗
0285-Plasmapheresis/Plasma Exchange/Therapeutic Apheresis0285 · Commercial37Original policy ↗
0845-Carfilzomib (Kyprolis)0845 · Commercial38Original policy ↗
0897-Mepolizumab (Nucala)0897 · Commercial38Original policy ↗
0997-Anifrolumab-fnia (Saphnelo)0997 · Commercial38Original policy ↗
0024-Aldesleukin (Proleukin)0024 · Commercial39Original policy ↗
0807-Eculizumab0807 · Commercial39Original policy ↗
0881-Canakinumab (Ilaris)0881 · Commercial39Original policy ↗
0904-Daratumumab (Darzalex) and Daratumumab and Hyaluronidase-fihj (Darzalex Faspro)0904 · Commercial39Original policy ↗
Carbon Dioxide Laser0427 · Commercial39Original policy ↗
Etanercept0315 · Commercial39Original policy ↗
1002-Efgartigimod Alfa-fcab (Vyvgart) and Efgartigimod Alfa and Hyaluronidase-qvfc (Vyvgart Hytrulo)1002 · Commercial42Original policy ↗
0732-Guillain-Barre Syndrome Treatments0732 · Commercial43Original policy ↗
0679-Levator Syndrome Treatments0679 · Commercial45Original policy ↗
0925-Benralizumab (Fasenra)0925 · Commercial46Original policy ↗
0818-Belimumab (Benlysta)0818 · Commercial47Original policy ↗
0823-Brentuximab Vedotin (Adcetris)0823 · Commercial47Original policy ↗
1098-Depemokimab-ulaa (Exdensur)1098 · Commercial49Original policy ↗
0975-Inebilizumab-cdon (Uplizna)0975 · Commercial50Original policy ↗
Headaches: Nonsurgical Management0462 · Commercial50Original policy ↗
0027-Vasectomy Procedures and Chronic Scrotal Content Pain0027 · Commercial52Original policy ↗
0877-Obinutuzumab (Gazyva)0877 · Commercial52Original policy ↗
0885-Vedolizumab (Entyvio)0885 · Commercial52Original policy ↗
0978-Lurbinectedin (Zepzelca)0978 · Commercial53Original policy ↗
0253-Vocal Cord Paralysis/Insufficiency Treatments0253 · Commercial54Original policy ↗
Hypertrophic Scars and Keloids0389 · Commercial56Original policy ↗
Certolizumab Pegol (Cimzia)0761 · Commercial59Original policy ↗
0400-Eagle's and Ernest Syndrome0400 · Commercial61Original policy ↗
0912-Ustekinumab0912 · Commercial61Original policy ↗
0937-Sinus Surgeries0937 · Commercial61Original policy ↗
0953-Onasemnogene Abeparvovec (Zolgensma and Itvisma)0953 · Commercial62Original policy ↗
Adalimumab0655 · Commercial62Original policy ↗
1003-Tezepelumab-ekko (Tezspire)1003 · Commercial64Original policy ↗
Abatacept (Orencia)0720 · Commercial64Original policy ↗
Glaucoma Surgery0484 · Commercial65Original policy ↗

Back to Meritain Eldorado

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.